NCT03754400 is a NA clinical trial of Albumin in Acute on Chronic Liver Failure, sponsored by Institute of Liver and Biliary Sciences, India.

Who is sponsoring NCT03754400?

NCT03754400 is sponsored by Institute of Liver and Biliary Sciences, India.

What drugs are being tested in NCT03754400?

Interventions in NCT03754400: Albumin, Standard Medical Treatment.

What condition does NCT03754400 study?

NCT03754400 studies Acute on Chronic Liver Failure.

Is NCT03754400 still recruiting?

NCT03754400 is currently status unknown. Last updated 8 April 2020.

Last reviewed 2020-04-08 · How we verify

NCT03754400

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Albumin Therapy With Standard Medical Treatment (SMT) as Compared to Standard Medical Treatment (SMT) in Improving Patient Survival and Immune Modulation in Patients With Acute on Chronic Liver Failure (ASIA Trial).

Status unknown NA Last updated 8 April 2020

What this trial tests

NA trial testing Albumin in Acute on Chronic Liver Failure in 200 participants. Status unknown.

Timeline

10 September 2018

Primary endpoint
30 July 2020

30 July 2020

Quick facts

Lead sponsor	Institute of Liver and Biliary Sciences, India
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	10 September 2018
Primary completion	30 July 2020
Estimated completion	30 July 2020
Sites	1 location across India

Drugs / interventions tested

Albumin — full drug profile →
Standard Medical Treatment — full drug profile →

Conditions studied

Acute on Chronic Liver Failure — all drugs for Acute on Chronic Liver Failure →

Sponsor

Institute of Liver and Biliary Sciences, India

Who can join

Adults 18 to 65, any sex, with Acute on Chronic Liver Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The AIM of the study is to study the efficacy of intravenous albumin and standard medical treatment as compared to standard medical treatment alone in ameliorating/preventing SIRS and improving survival at 28 days .The project will be conducted in ILBS from august 2018 to December 2019Concept is to understand the immunology, pathophysiology and effects of albumin in the management of ACLF for betterment of the patient's condition and early recovery. All ACLF patients will be included as per the inclusion and exclusion criteria , after taking informed consent from the patient or their relatives. Will be evaluated for the possible risk factors for the development of SIRS/sepsis in ACLF patients and possible beneficial factors for resolution of SIRS /sepsis in ACLF patients. The effects of albumin administration as per this protocol versus standard medical treatment alone will be reviewed If patient develops allergic reactions to albumin, fluid overload, albumin will be stopped and patient will be treated accordingly to medical condition.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Gut microbiota mediated molecular events and therapy in liver diseases.
Qi X, Yang M, Stenberg J, Dey R, et al · · 2020 · cited 20× · PMID 33505139 · DOI 10.3748/wjg.v26.i48.7603

Verify or expand the search:

Other trials of Albumin

Trials testing the same drug.

NCT07395141 — Albumin in Acute Variceal Bleeding · Phase 3 · not yet recruiting
NCT07263308 — Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2 · Phase 3 · recruiting
NCT07002827 — Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standar · NA · not yet recruiting
NCT06809088 — Comparison of Safety and Efficacy of Tailored Versus Fixed Dose Albumin for the Management of Patients With Cirrhosis an · NA · not yet recruiting
NCT06654687 — Transthoracic Echocardiographic Monitoring of Cardiac Output Effects of Colloid Preload and Crystalloid Coload During Ce · NA · completed

Other Institute of Liver and Biliary Sciences, India trials

Trials by the same sponsor.

NCT07480005 — To Revisit the Yield of Staging Laparoscopy in Hepatopancreatobiliary Malignancies · recruiting
NCT07480057 — Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry · recruiting
NCT07465471 — Carvedilol and Midodrine Versus Carvedilol Alone in Preventing Early Rebleed in Patients With Cirrhosis. · NA · not yet recruiting
NCT07433881 — Serosurvey of HAV Immunity and Single-dose Vaccine Immunogenicity Among Patients With Cirrhosis · not yet recruiting
NCT07422948 — Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03754400 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Liver and Biliary Sciences, India
Last refreshed: 8 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03754400.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing